FAM83B mediates EGFR- and RAS-driven oncogenic transformation.

Aberrant regulation of growth signaling is a hallmark of cancer development that often occurs through the constitutive activation of growth factor receptors or their downstream effectors. Using validation-based insertional mutagenesis (VBIM), we identified family with sequence similarity 83, member B (FAM83B), based on its ability to substitute for RAS in the transformation of immortalized human mammary epithelial cells (HMECs). We found that FAM83B coprecipitated with a downstream effector of RAS, CRAF. Binding of FAM83B with CRAF disrupted CRAF/14-3-3 interactions and increased CRAF membrane localization, resulting in elevated MAPK and mammalian target of rapamycin (mTOR) signaling. Ablation of FAM83B inhibited the proliferation and malignant phenotype of tumor-derived cells or RAS-transformed HMECs, implicating FAM83B as a key intermediary in EGFR/RAS/MAPK signaling. Analysis of human tumor specimens revealed that FAM83B expression was significantly elevated in cancer and was associated with specific cancer subtypes, increased tumor grade, and decreased overall survival. Cumulatively, these results suggest that FAM83B is an oncogene and potentially represents a new target for therapeutic intervention.

[1]  L. Mayo,et al.  Inactivation of p53 signaling by p73 or PTEN ablation results in a transformed phenotype that remains susceptible to Nutlin-3 mediated apoptosis , 2010, Cell cycle.

[2]  H. Brown,et al.  Biochemical analysis of phospholipase D. , 2007, Methods in enzymology.

[3]  M. Jackson,et al.  TGF-β signaling engages an ATM-CHK2-p53–independent RAS-induced senescence and prevents malignant transformation in human mammary epithelial cells , 2011, Proceedings of the National Academy of Sciences.

[4]  M. Jackson,et al.  MdmX Protects p53 from Mdm2-Mediated Degradation , 2000, Molecular and Cellular Biology.

[5]  J. Exton,et al.  Association of N- and C-terminal Domains of Phospholipase D Is Required for Catalytic Activity* , 1998, The Journal of Biological Chemistry.

[6]  P. Pandolfi,et al.  Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. , 2008, The Journal of clinical investigation.

[7]  Weifeng Chen,et al.  BJ-TSA-9, a novel human tumor-specific gene, has potential as a biomarker of lung cancer. , 2005, Neoplasia.

[8]  G. Stark,et al.  Limited role of N-terminal phosphoserine residues in the activation of transcription by p53 , 2004, Oncogene.

[9]  C. Ottmann,et al.  Impaired Binding of 14-3-3 to C-RAF in Noonan Syndrome Suggests New Approaches in Diseases with Increased Ras Signaling , 2010, Molecular and Cellular Biology.

[10]  Richard Marais,et al.  The RAF proteins take centre stage , 2004, Nature Reviews Molecular Cell Biology.

[11]  David L. Brautigan,et al.  Raf-1 activates MAP kinase-kinase , 1992, Nature.

[12]  G. Stark,et al.  p53-mediated growth suppression in response to Nutlin-3 in cyclin D1 transformed cells occurs independently of p21. , 2007, Cancer research.

[13]  Taylor Jensen,et al.  Epigenetic inactivation of the HOXA gene cluster in breast cancer. , 2006, Cancer research.

[14]  Sarah A. Scott,et al.  Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. , 2009, Nature chemical biology.

[15]  D. A. Foster,et al.  Phospholipase D in cell proliferation and cancer. , 2003, Molecular cancer research : MCR.

[16]  T. Yeatman,et al.  Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. , 2008, Cancer research.

[17]  W. Hahn,et al.  Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. , 2001, Genes & development.

[18]  G. Stark,et al.  Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. , 2006, Cancer research.

[19]  Paul Tempst,et al.  Phosphorylation and Functional Inactivation of TSC2 by Erk Implications for Tuberous Sclerosisand Cancer Pathogenesis , 2005, Cell.

[20]  M. Toi,et al.  Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. , 1991, European journal of cancer.

[21]  M. Shi,et al.  Phospholipase D provides a survival signal in human cancer cells with activated H-Ras or K-Ras. , 2007, Cancer letters.

[22]  M. Bissell,et al.  FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice. , 2012, The Journal of clinical investigation.

[23]  C. Schem,et al.  Significance of Tyrosine Kinase Inhibitors in the Treatment of Metastatic Breast Cancer , 2009, Breast Care.

[24]  S. Elledge,et al.  Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1 , 1993, Nature.

[25]  E. Kandel,et al.  Validation-based insertional mutagenesis identifies lysine demethylase FBXL11 as a negative regulator of NFκB , 2009, Proceedings of the National Academy of Sciences.

[26]  L. Chin,et al.  A Genetic Screen for Candidate Tumor Suppressors Identifies REST , 2005, Cell.

[27]  J. Downward.  Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.